Targeted drug combo with radiation for advanced bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with bile duct or gallbladder cancer that cannot be removed with surgery.
- You have not had any prior treatment for this cancer.
- You have at least one tumor that can be measured on a scan.
- You are generally well enough to care for yourself (ECOG score 0 or 1).
- Your liver, kidney, and blood counts are within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
This trial tests a combination treatment for biliary tract cancer that is borderline resectable or locally advanced. It combines a chemotherapy infusions directly into the liver (HAIC) with an immunotherapy drug (adebrelimab) and a targeted therapy pill (lenvatinib), aiming to shrink the tumor enough to allow surgery.
This trial tests a combination of three treatments—chemotherapy delivered directly to the liver, plus two immunotherapy drugs—for advanced bile duct cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment and is safe for patients.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.